Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 58

Publication Record

Connections

Health Care Costs and Cost-effectiveness in Laryngotracheal Stenosis.
Yin LX, Padula WV, Gadkaree S, Motz K, Rahman S, Predmore Z, Gelbard A, Hillel AT
(2019) Otolaryngol Head Neck Surg 160: 679-686
MeSH Terms: Adult, Cost-Benefit Analysis, Dilatation, Endoscopy, Female, Health Care Costs, Humans, Laryngostenosis, Male, Middle Aged, Quality-Adjusted Life Years, Retrospective Studies, Tracheal Stenosis, Tracheotomy
Show Abstract · Added July 30, 2020
OBJECTIVE - Laryngotracheal stenosis (LTS) is resource-intensive disease. The cost-effectiveness of LTS treatments has not been adequately explored. We aimed to conduct a cost-effectiveness analysis comparing open reconstruction (cricotracheal/tracheal resection [CTR/TR]) with endoscopic dilation in the treatment of LTS.
STUDY DESIGN - Retrospective cohort.
SETTING - Tertiary referral center (2013-2017).
SUBJECTS AND METHODS - Thirty-four LTS patients were recruited. Annual costs were derived from the Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University. Cost-effectiveness analysis compared CTR/TR versus endoscopic dilation at a willingness-to-pay threshold of $50,000 per quality-adjusted life year (QALY) over 5- and 10-year time horizons. The incremental cost-effectiveness ratio (ICER) was calculated with deterministic analysis and tested for sensitivity with univariate and probabilistic sensitivity analysis.
RESULTS - Mean LTS costs were $4080.09 (SE, $569.29) annually for related health care visits. The major risk factor for increased cost was etiology of stenosis. As compared with idiopathic patients, patients with intubation-related stenosis had significantly higher annual costs ($5286.56 vs $2873.62, P = .03). The cost of CTR/TR was $8583.91 (SE, $2263.22). Over a 5-year time horizon, CTR/TR gained $896 per QALY over serial dilations and was cost-effective. Over a 10-year time horizon, CTR/TR dominated dilations with a lower cost and higher QALY.
CONCLUSION - The cost of treatment for LTS is significant. Patients with intubation-related stenosis have significantly higher annual costs than do idiopathic patients. CTR/TR contributes significantly to cost in LTS but is cost-effective versus endoscopic dilations for appropriately selected patients over a 5- and 10-year horizon.
0 Communities
1 Members
0 Resources
MeSH Terms
Cost Effectiveness of Gastric Cancer Screening According to Race and Ethnicity.
Saumoy M, Schneider Y, Shen N, Kahaleh M, Sharaiha RZ, Shah SC
(2018) Gastroenterology 155: 648-660
MeSH Terms: African Americans, Continental Population Groups, Cost-Benefit Analysis, Early Detection of Cancer, Ethnic Groups, European Continental Ancestry Group, Female, Gastroscopy, Hispanic Americans, Humans, Male, Markov Chains, Mass Screening, Middle Aged, Quality-Adjusted Life Years, Stomach Neoplasms, United States
Show Abstract · Added March 3, 2020
BACKGROUND & AIMS - There are marked racial and ethnic differences in non-cardia gastric cancer prevalence within the United States. Although gastric cancer screening is recommended in some regions of high prevalence, screening is not routinely performed in the United States. Our objective was to determine whether selected non-cardia gastric cancer screening for high-risk races and ethnicities within the United States is cost effective.
METHODS - We developed a decision analytic Markov model with the base case of a 50-year-old person of non-Hispanic white, non-Hispanic black, Hispanic, or Asian race or ethnicity. The cost effectiveness of a no-screening strategy (current standard) for non-cardia gastric cancer was compared with that of 2 endoscopic screening modalities initiated at the time of screening colonoscopy for colorectal cancer: upper esophagogastroduodenoscopy with biopsy examinations and continued surveillance only if intestinal metaplasia or more severe pathology is identified or esophagogastroduodenoscopy with biopsy examinations continued every 2 years even in the absence of identified pathology. We used prevalence rates, transition probabilities, costs, and quality-adjusted life years (QALYs) from publications and public data sources. Outcome measures were reported in incremental cost-effectiveness ratios, with a willingness-to-pay threshold of $100,000/QALY.
RESULTS - Compared with biennial and no screening, screening esophagogastroduodenoscopy with continued surveillance only when indicated was cost effective for non-Hispanic blacks ($80,278/QALY), Hispanics ($76,070/QALY), and Asians ($71,451/QALY), but not for non-Hispanic whites ($122,428/QALY). The model was sensitive to intestinal metaplasia prevalence, transition rates from intestinal metaplasia to dysplasia to local and regional cancer, cost of endoscopy, and cost of resection (endoscopic or surgical).
CONCLUSIONS - Based on a decision analytic Markov model, endoscopic non-cardia gastric cancer screening for high-risk races and ethnicities could be cost effective in the United States.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.
0 Communities
1 Members
0 Resources
MeSH Terms
Improving the value of care for appendectomy through an individual surgeon-specific approach.
Robinson JR, Carter NH, Gibson C, Brinkman AS, Van Arendonk K, Speck KE, Danko ME, Jackson GP, Lovvorn HN, Blakely ML
(2018) J Pediatr Surg 53: 1181-1186
MeSH Terms: Adolescent, Appendectomy, Appendicitis, Child, Child, Preschool, Cost-Benefit Analysis, Female, Hospital Costs, Humans, Infant, Infant, Newborn, Laparoscopy, Male, Operating Rooms, Prospective Studies, Quality of Health Care, Surgeons, Tennessee, Treatment Outcome
Show Abstract · Added June 27, 2018
PURPOSE - Standardized care via a unified surgeon preference card for pediatric appendectomy can result in significant cost reduction. The purpose of this study was to evaluate the impact of cost and outcome feedback to surgeons on value of care in an environment reluctant to adopt a standardized surgeon preference card.
METHODS - Prospective observational study comparing operating room (OR) supply costs and patient outcomes for appendectomy in children with 6-month observation periods both before and after intervention. The intervention was real-time feedback of OR supply cost data to individual surgeons via automated dashboards and monthly reports.
RESULTS - Two hundred sixteen children underwent laparoscopic appendectomy for non-perforated appendicitis (110 pre-intervention and 106 post-intervention). Median supply cost significantly decreased after intervention: $884 (IQR $705-$1025) to $388 (IQR $182-$776), p<0.001. No significant change was detected in median OR duration (47min [IQR 36-63] to 50min [IQR 38-64], p=0.520) or adverse events (1 [0.9%] to 6 [4.7%], p=0.062). OR supply costs for individual surgeons significantly decreased during the intervention period for 6 of 8 surgeons (87.5%).
CONCLUSION - Approaching value measurement with a surgeon-specific (rather than group-wide) approach can reduce OR supply costs while maintaining excellent clinical outcomes.
LEVEL OF EVIDENCE - Level II.
Copyright © 2018 Elsevier Inc. All rights reserved.
0 Communities
2 Members
0 Resources
19 MeSH Terms
The Devil Is in the Details When Removing Cervical Collars After Blunt Trauma.
Patel MB, Como JJ, Haut ER
(2018) JAMA Surg 153: 632-633
MeSH Terms: Cost-Benefit Analysis, Humans, Magnetic Resonance Imaging, Spinal Injuries, Wounds, Nonpenetrating
Added June 26, 2018
0 Communities
1 Members
0 Resources
5 MeSH Terms
Cost-effective management of pelvic fracture urethral injuries.
Johnsen NV, Penson DF, Reynolds WS, Milam DF, Dmochowski RR, Kaufman MR
(2017) World J Urol 35: 1617-1623
MeSH Terms: Adult, Cost-Benefit Analysis, Fractures, Bone, Humans, Lower Urinary Tract Symptoms, Male, Models, Economic, Patient Care Management, Pelvic Bones, Reconstructive Surgical Procedures, United States, Urethra, Urethral Stricture, Urologic Surgical Procedures, Wounds, Nonpenetrating
Show Abstract · Added September 16, 2019
PURPOSE - To compare the cost-effectiveness of various treatment strategies in the management of pelvic fracture urethral injuries using decision analysis.
METHODS - Five strategies were modeled from the time of injury to resolution of obstructed voiding or progression to urethroplasty. Management consisted of immediate suprapubic tube (SPT) placement and delayed urethroplasty; primary endoscopic realignment (PER) followed by urethroplasty in failed patients; or PER followed by 1-3 direct vision internal urethrotomies (DVIU), followed by urethroplasty. Success rates were obtained from the literature. Total medical costs were estimated and incremental cost-effectiveness ratios (ICERs) were generated over a 2-year follow-up period.
RESULTS - PER was preferred over SPT placement in all iterations of the model. PER followed by a single DVIU and urethroplasty in cases of failure was least costly and used as the referent approach with an average cost-effectiveness of $17,493 per unobstructed voider. The ICER of a second DVIU prior to urethroplasty was $86,280 per unobstructed voider, while the ICER of a third DVIU was $172,205. The model was sensitive to changes in the success rate of the first DVIU, where when the probability of DVIU success is expected to be less than 32% immediate urethroplasty after failed PER is favored.
CONCLUSIONS - Management of pelvic fracture urethral injuries with PER is the preferred management strategy according to the current model. For those who fail PER, a single DVIU may be attempted if the presumed success rate is >32%. In all other cases, urethroplasty following PER is the preferred approach.
0 Communities
1 Members
0 Resources
MeSH Terms
Measuring the Value of a Clinical Practice Guideline for Children With Perforated Appendicitis.
Robinson JR, Avritscher EBC, Gay JC, Willis ZI, Putnam LR, Anglemyer A, Pedroza C, Tyson JE, Blakely ML
(2017) Ann Surg 266: 195-200
MeSH Terms: Abdominal Abscess, Anti-Bacterial Agents, Appendectomy, Appendicitis, Child, Cost Savings, Cost-Benefit Analysis, Female, Hospital Costs, Humans, Intestinal Perforation, Male, Postoperative Complications, Practice Guidelines as Topic
Show Abstract · Added January 16, 2017
OBJECTIVE - To determine the incremental cost-effectiveness of a clinical practice guideline (CPG) compared with "usual care" for treatment of perforated appendicitis in children. Secondary objective was to compare cost analyses using hospital accounting system data versus data in the Pediatric Health Information System (PHIS).
BACKGROUND - Value-based surgical care (outcomes relative to costs) is frequently touted, but outcomes and costs are rarely measured together.
METHODS - During an 18-month period, 122 children with perforated appendicitis at a tertiary referral children's hospital were treated using an evidence-based CPG. Clinical outcomes and costs for the CPG cohort were compared with patients in the 30-month period before CPG implementation (n = 191 children).
RESULTS - With CPG-directed care, intra-abdominal abscess rate decreased from 0.24 to 0.10 (adjusted risk ratio 0.44, 95% confidence interval [CI] 0.26-0.75). The rate of any adverse event decreased from 0.30 to 0.23 (adjusted risk ratio 0.82, 95% CI 0.58-1.17). Mean total hospital costs per patient (hospital accounting system) decreased from $16,466 to $10,528 (adjusted absolute difference-$5451, 95% CI -$7755 to -$3147), leading to estimated adjusted total savings of $665,022 during the study period. Costs obtained from the PHIS database also showed reduction with CPG-directed care (-$6669, 95% CI -$8949 to -$4389 per patient). In Bayesian cost-effectiveness analyses, likelihood that CPG was the dominant strategy was 91%.
CONCLUSIONS - An evidence-based CPG increased the value of surgical care for children with perforated appendicitis by improving outcomes and lowering costs. Hospital cost accounting data and pre-existing cost data within the PHIS database provided similar results.
0 Communities
1 Members
0 Resources
14 MeSH Terms
Is the Juice Worth the Squeeze? Costs and Benefits of Multiple Human Annotators for Clinical Text De-identification.
Carrell DS, Cronkite DJ, Malin BA, Aberdeen JS, Hirschman L
(2016) Methods Inf Med 55: 356-64
MeSH Terms: Cost-Benefit Analysis, Data Mining, Electronic Health Records, Humans, Patient Identification Systems
Show Abstract · Added April 10, 2018
BACKGROUND - Clinical text contains valuable information but must be de-identified before it can be used for secondary purposes. Accurate annotation of personally identifiable information (PII) is essential to the development of automated de-identification systems and to manual redaction of PII. Yet the accuracy of annotations may vary considerably across individual annotators and annotation is costly. As such, the marginal benefit of incorporating additional annotators has not been well characterized.
OBJECTIVES - This study models the costs and benefits of incorporating increasing numbers of independent human annotators to identify the instances of PII in a corpus. We used a corpus with gold standard annotations to evaluate the performance of teams of annotators of increasing size.
METHODS - Four annotators independently identified PII in a 100-document corpus consisting of randomly selected clinical notes from Family Practice clinics in a large integrated health care system. These annotations were pooled and validated to generate a gold standard corpus for evaluation.
RESULTS - Recall rates for all PII types ranged from 0.90 to 0.98 for individual annotators to 0.998 to 1.0 for teams of three, when meas-ured against the gold standard. Median cost per PII instance discovered during corpus annotation ranged from $ 0.71 for an individual annotator to $ 377 for annotations discovered only by a fourth annotator.
CONCLUSIONS - Incorporating a second annotator into a PII annotation process reduces unredacted PII and improves the quality of annotations to 0.99 recall, yielding clear benefit at reasonable cost; the cost advantages of annotation teams larger than two diminish rapidly.
0 Communities
1 Members
0 Resources
MeSH Terms
The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents.
Kreimer AR, Sherman ME, Sahasrabuddhe VV, Safaeian M
(2015) J Natl Cancer Inst 107:
MeSH Terms: Adolescent, Cost-Benefit Analysis, Dose-Response Relationship, Drug, Female, Humans, Immunization Schedule, Papillomavirus Infections, Papillomavirus Vaccines, Randomized Controlled Trials as Topic, Research Design, United States, Uterine Cervical Neoplasms
Added March 17, 2015
0 Communities
1 Members
0 Resources
12 MeSH Terms
Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system.
Liu FX, Walton SM, Leipold R, Isbell D, Golper TA
(2014) Perit Dial Int 34: 749-57
MeSH Terms: Adult, Aged, Cost-Benefit Analysis, Female, Health Care Costs, Humans, Kidney Failure, Chronic, Male, Medicare, Middle Aged, Models, Economic, Peritoneal Dialysis, Prospective Payment System, Renal Dialysis, United States
Show Abstract · Added August 7, 2015
BACKGROUND - The economic burden of treating end-stage renal disease (ESRD) continues to grow. As one response, effective January 1, 2011, Medicare implemented a bundled prospective payment system (PPS, including injectable drugs) for dialysis patients. This study investigated the 5-year budget impact on Medicare under the new PPS of changes in the distribution of patients undergoing peritoneal dialysis (PD), in-center hemodialysis (ICHD), and home hemodialysis (HHD).
METHODS - An Excel-based budget impact model was created to assess dialysis-associated Medicare costs. The model accounted for dialysis access establishment, the current monthly capitation physician payment for ESRD, Medicare dialysis payments (including start-up costs), training, oral drug costs, and the costs and probabilities of adverse events including access failure, hospitalization for access infection, pneumonia, septicemia, and cardiovascular events. United States Renal Data System (USRDS) data were used to project the US Medicare dialysis patient population across time. The baseline scenario assumed a stable distribution of PD (7.7%), HHD (1.3%) and ICHD (91.0%) over 5 years. Three comparison scenarios raised the proportions of PD and HHD by (1) 1% and 0.5%, (2) 2% and 0.75%, and (3) 3% and 1% each year; a fourth scenario held HHD constant and lowered PD by 1% per year.
RESULTS - Under the bundled PPS, scenarios that increased PD and HHD from 7.7% and 1.3% over 5 years resulted in cumulative savings to Medicare of $114.8M (Scenario 1, 11.7% PD and 3.3% HHD at year 5), $232.9M (Scenario 2, 15.7% PD and 4.3% HHD at year 5), and $350.9M (Scenario 3, 19.7% PD and 5.3% HHD at year 5). When the PD population was decreased from 7.7% in 2013 to 3.7% by 2017 with a constant HHD population, the total Medicare payment for dialysis patients increased by over $121.2M.
CONCLUSIONS - Under Medicare bundled PPS, increasing the proportion of patients on PD and HHD vs ICHD could generate substantial savings in dialysis-associated costs to Medicare.
Copyright © 2014 International Society for Peritoneal Dialysis.
0 Communities
1 Members
0 Resources
15 MeSH Terms
Cost-effectiveness of initial diagnostic strategies for pulmonary nodules presenting to thoracic surgeons.
Deppen SA, Davis WT, Green EA, Rickman O, Aldrich MC, Fletcher S, Putnam JB, Grogan EL
(2014) Ann Thorac Surg 98: 1214-22
MeSH Terms: Biopsy, Fine-Needle, Bronchoscopy, Cost-Benefit Analysis, Decision Support Techniques, Fluorodeoxyglucose F18, Humans, Lung Neoplasms, Male, Middle Aged, Positron-Emission Tomography, Quality-Adjusted Life Years, Solitary Pulmonary Nodule, Surgeons, Thoracic Surgery, Video-Assisted, Tomography, X-Ray Computed
Show Abstract · Added October 28, 2015
BACKGROUND - Patients presenting to thoracic surgeons with pulmonary nodules suggestive of lung cancer have varied diagnostic options including navigation bronchoscopy (NB), computed tomography-guided fine-needle aspiration (CT-FNA), (18)F-fluoro-deoxyglucose positron emission tomography (FDG-PET) and video-assisted thoracoscopic surgery (VATS). We studied the relative cost-effective initial diagnostic strategy for a 1.5- to 2-cm nodule suggestive of cancer.
METHODS - A decision analysis model was developed to assess the costs and outcomes of four initial diagnostic strategies for diagnosis of a 1.5- to 2-cm nodule with either a 50% or 65% pretest probability of cancer. Medicare reimbursement rates were used for costs. Quality-adjusted life years were estimated using patient survival based on pathologic staging and utilities derived from the literature.
RESULTS - When cancer prevalence was 65%, tissue acquisition strategies of NB and CT-FNA had higher quality-adjusted life years compared with either FDG-PET or VATS, and VATS was the most costly strategy. In sensitivity analyses, NB and CT-FNA were more cost-effective than FDG-PET when FDG-PET specificity was less than 72%. When cancer prevalence was 50%, NB, CT-FNA, and FDG-PET had similar cost-effectiveness.
CONCLUSIONS - Both NB and CT-FNA diagnostic strategies are more cost-effective than either VATS biopsy or FDG-PET scan to diagnose lung cancer in moderate- to high-risk nodules and resulted in fewer nontherapeutic operations when FDG-PET specificity was less than 72%. An FDG-PET scan for diagnosis of lung cancer may not be cost-effective in regions of the country where specificity is low.
Copyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
0 Communities
1 Members
0 Resources
15 MeSH Terms